Article: The Growth in Disease Registries by Bill Crown

The current policy environment has broadened the scope of evidence that life-sciences companies must provide to healthcare stakeholders. In the United States, the focus is on comparative effectiveness research (CER), and in many other parts of the world, relative effectiveness/efficacy.

View the full article to learn more about the growing role of disease registries in evidence generation.